To evaluate the presence of vascular damage in long-term childhood cancer survivors (CCS) and sibling controls, and to evaluate the association between vascular damage parameters and cancer treatment and influence of cardiovascular risk factors.
INTRODUCTION
Clinical cardiovascular disease is markedly increased in childhood cancer survivors (CCSs) compared with the background population. [1] [2] [3] An initial step in the development of cardiovascular disease is endothelial damage. In the general population, increased intima-media thickness (IMT) of the carotid artery is considered to be an early marker for atherosclerosis and is associated with an increased risk of cardiovascular events. 4 Mounting evidence indicates that increased IMT of the carotid artery is a risk factor for adverse cardiovascular outcome. 5, 6 Carotid-artery IMT was found to be increased in small studies in CCSs after cranial and/or neck radiotherapy (RT). [7] [8] [9] Impaired endotheliumdependent vasodilatation was demonstrated to be associated with previously administered RT or anthracyclines. [10] [11] [12] In survivors of adult cancers, we and others have shown that early signs of vascular damage were frequently accompanied by an unfavorable cardiovascular risk profile. 13, 14 Other researchers found elevated systolic blood pressure (BP), dyslipidemia, and increased carotid-bulb IMT in childhood brain tumor survivors treated with craniospinal RT 7 or after neck irradiation. 9 In addition, increased prevalence of cardiovascular risk factors (CRFs) was reported in survivors of childhood acute lymphoblastic leukemia, especially after cranial irradiation.
To better define the presence of long-term vascular damage and endothelial activation in a large cohort, we performed a singlecenter cross-sectional study in 277 adult CCSs after potentially cardiovascularly toxic anticancer treatment. The objectives of this study were to evaluate: parameters of vascular damage (ie, IMT of carotid and femoral arteries, endothelial and inflammatory marker proteins) in CCSs compared with controls, association between parameters of vascular damage and previous cancer treatment, and association between vascular damage and current status of CRFs in long-term CCSs.
PATIENTS AND METHODS

Study Design
This was a single-center study of late cardiovascular changes in adult CCSs. Eligibility criteria were: childhood cancer diagnosis between 1976 and 1999, potentially cardiovascularly toxic treatment (anthracyclines, platinum, and/or RT directed to head, neck, spine, or trunk), age at diagnosis Յ 20 years, current age Ն 18 years, survival Ն 5 years after diagnosis, no treatment for secondary tumor or late relapse Ն 5 years after diagnosis, and no pre-existing cardiovascular disease and/or Down syndrome at cancer diagnosis.
Study Population
A total of 452 patients met the eligibility criteria (Fig 1) . Of these CCSs, 46 died Ն 5 years after diagnosis, and 22 CCSs were excluded Ն 5 years after diagnosis for other reasons (Fig 1) , leaving 384 CCSs who could be asked to participate in this study. No differences in age at diagnosis, sex, or type of treatment were found between the 277 participating and 107 nonparticipating survivors. Additional details of this cohort were previously reported. 17 Of the 277 participating CCSs, 14 were receiving growth hormone replacement therapy, and eight received cardioactive medication (angiotensinconverting enzyme inhibitor, beta blocker, or diuretic). Controls were recruited from healthy siblings of the participating CCSs nearest to them in age (n ϭ 130).
The study protocol was approved by the institutional ethics committee. Written informed consent was obtained from all participants. All assessments were performed between 2004 and 2007.
Methods
Data on cancer treatment, smoking, and medication were obtained from medical records and during assessment. Physical examination included measurement of BP (twice on both arms in supine position after Ն 10 minutes rest), height, and weight. Criteria for hypertension were systolic BP Ն 140 mmHg, diastolic BP Ն 90 mmHg, and/or treatment with antihypertensive drugs. Body-mass index (BMI) was calculated by weight (kg) over height squared (m 2 ). Underweight was defined as BMI Ͻ 18.5 kg/m 2 , and overweight was defined as BMI Ն 25 kg/m 2 . Vascular structure was determined by IMT measurements using the Acuson 128 XP ultrasound system (Acuson, Mountain View, CA) with a 7-MHz linear array transducer, as described earlier. 18 The far-wall segments of the common carotid artery, carotid bulb, and internal carotid were imaged from a lateral transducer position, and those of the femoral arterial walls were imaged from an anterior transducer position. The highest IMT value found in a segment was considered to be the maximum IMT, and the mean of three measurements in this segment was considered to be the mean IMT. The end point was the mean maximal thickness of the far-wall IMT of the six imaged carotid segments and of the four femoral segments. In addition, carotid distensibility and compliance were determined.
18
Vascular function was assessed by brachial artery flow-mediated dilation (FMD), using a wall tracking system consisting of an ultrasound scanning device (Wall Tracking System 2.0, Pie Medical Esaote AU-5; Pie Medical, Maastricht, the Netherlands), as described earlier.
19 All measurements were performed by a single technician blinded to participant characteristics.
Fasting blood samples were analyzed according to routine procedures for lipid spectrum (plasma total, LDL and HDL cholesterol, and triglycerides High-sensitivity C-reactive protein (CRP; serum [mg/L]) was measured by nephelometry as a marker for acute-phase response. Von Willebrand factor as a parameter for endothelial cell activation was measured in citrate plasma via enzyme-linked immunosorbent assay (ELISA; Dako, Glostrup, Denmark). Plasminogen activator inhibitor type 1 (PAI-1; ng/mL) and tissue-type plasminogen activator (t-PA; ng/mL) levels were determined in citrate plasma using ELISA Asserachrom PAI and Asserachrom t-PA (Roche, Basel, Switzerland) to estimate fibrinolytic activity.
A 24 hours, urine sample was analyzed for albumin (mg/L) by nephelometry and creatinine (mmol/L). Renal function was calculated by creatinine Inclusion criteria: (a) childhood cancer diagnosis between 1976-1999; (b) treated with anthracyclines, platinum, and/or RT; (c) age at diagnosis ≤ 20 years; (d) current age ≥ 18 years; (e) survived ≥ 5 years after diagnosis; (f) no treatment for secondary tumor or late relapse ≥ 5 years after diagnosis; (g) no pre-existing cardiovascular disease and/or Down syndrome at diagnosis Died ≥ 5 years after diagnosis (n = 46) Secondary tumor/late relapse (n = 35) , and values Յ 60 mL/min/1.73 m 2 were considered renal dysfunction. Urinary albumin excretion Ն 30 mg per 24 hours was considered a sign of endothelial damage.
21,22
Treatment Variables
To evaluate vascular effects of the administered treatment, the following chemotherapy categories were analyzed: one, anthracycline-based (doxorubicin, daunorubicin) combination chemotherapy; and two, platinum-based (cisplatin, carboplatin) combination chemotherapy. Cumulative dose of anthracyclines was calculated by adding the doses of doxorubicin and daunorubicin, because both were considered equivalent. To evaluate the effect of RT on different sites such as carotid or femoral area, the following irradiation fields were analyzed as follows: any type of RT (RT to head, neck, trunk, or spine or total-body irradiation [TBI]; Table 1 ), divided into three RT groups (group 1: RT to neck, chest, or mediastinum only [not head or spine]; group 2: RT but not to neck, chest, abdomen, or pelvis [mainly cranial irradiation for brain tumors or leukemia]; group 3: RT to other locations, including chest and abdomen, kidney, pelvis, spine, or TBI; Table 1 ). The irradiation field for group one included the carotid arteries and/or aortic arch but not femoral arteries; the RT field for group two did not include the carotid or femoral areas; group three consisted of the remaining patients for whom RT was part of treatment, and the irradiation field included carotid and/or femoral areas. To evaluate the effect of RT on IMT of vessels in nonirradiated areas, group-three patients were not included in the tested treatment models because of heterogeneity and the difficulty of determining RT effects at specific locations (eg, carotid and femoral IMTs) in a uniform fashion for this group. Retrospective individual dosimetry was not available, because RT was administered before 1999.
Data Analyses and Statistics
Statistical analyses were performed with SPSS software (version 18; SPSS, Chicago, IL). Parameters with a non-Gaussian distribution were analyzed using nonparametric tests, and parameters with a Gaussian distribution were analyzed using parametric statistical tests. Two-sided P values Ͻ .05 were considered significant. We used regression analyses to investigate whether associations between IMT and age were different for CCSs and controls by including an interaction term.
Linear regression analyses were used to assess the association between the several cancer treatment groups and the outcome measures of carotid and femoral IMTs, FMD, and marker proteins. Treatment groups were tested in separate models with adjustment for the potential confounders age and sex.
Four models were constructed to analyze both the unadjusted and adjusted effects of treatment with anthracyclines or not, RT or not, and RT location versus other RT location.
Using logistic regression analyses, CRFs were compared between CCSs with IMT Ն 75th percentile (P 
RESULTS
Study Population and CRFs
Median age of the 277 participating CCSs was 27.5 years (range, 18.1 to 48.2 years); for the 130 controls, it was 25.9 years (range, 18.0 to 51.1 years; P ϭ .33) Treatment-related characteristics of the CCSs are summarized in Table 1 . At the time of the study, two CCSs (1%) received cholesterol-lowering medication, and 17 (6%) received cardioactive medication, but none of the controls did so. CRFs are summarized in Table 2 . Hypertension tended to be more prevalent in CCSs. The ratio of cholesterol to HDL cholesterol was higher in CCSs.
Vascular Damage and Cancer Treatment
Vascular structure measured by IMT of the carotid and femoral arteries did not differ between CCSs and controls (Table 3 ). In addition, vascular function as measured by FMD of the brachial artery was not different when comparing CCSs and controls.
The expected association between carotid IMT and current age did not differ between CCSs and controls (regression coefficient of difference [B], 0.001; 95% CI, Ϫ0.002 to 0.004). However, the association between femoral IMT and age was higher in CCSs (B, 0.004; 95% CI, 0.001 to 0.008), indicating a greater increase in femoral IMT with increasing age in CCSs compared with controls. Carotid artery distensibility as a measure for arterial stiffness was lower in CCSs, reflecting an increased mechanical load on the carotid vessel wall (Table 3) .
We assessed the association between treatment and carotid IMT, femoral IMT, and FMD using linear regression analyses. Four models were tested, with adjustment for potential confounders (Table 4) . Carotid IMT was positively associated with any RT and negatively associated with anthracyclines (both as categorical variable [yes v no] and per 100 mg/m 2 cumulative dose [data not shown]). Femoral IMT was positively associated with any RT but not with anthracyclines (Table 4 ). In the model with all treatment variables (ie, model four; Table 4 ), no effect of anthracyclines on IMT was found. The small size of the platinum group precluded its incorporation into the model. In model four, with all treatment variables, we observed a significant Abbreviations: RT, radiotherapy; TBI, total-body irradiation.
‫ء‬
Wilms tumor (n ϭ 16) and neuroblastoma (n ϭ 7). †Doxorubicin and/or daunorubicin. ‡Cisplatin and/or carboplatin.
influence of RT to neck and mediastinum on femoral IMT, indicating an off-target or systemic effect of irradiation. In model four, this effect was also present when additional adjustment for overweight and underweight at time of vascular assessment was performed (Appendix Table A1 , online only). We found no association between FMD and any of the treatment groups (Appendix Table A2 , online only).
Vascular Marker Proteins and Cancer Treatment
Compared with controls, CCSs had higher t-PA and PAI-I levels and higher ratio of urinary albumin to creatinine, whereas Von Willebrand factor and high-sensitivity CRP were similar ( Table 3) . The association between treatment and endothelial and inflammatory marker proteins was analyzed in linear regression models (Appendix 
‫ء‬
Hypertension defined as systolic blood pressure Ն 140 mmHg and/or diastolic blood pressure Ն 90 mmHg and/or use of antihypertensive medication (excluding eight survivors with no hypertension but receiving cardioactive treatment because of systolic heart failure ͓n ϭ 7͔ or tubular dysfunction ͓n ϭ 1͔).
†Excluding 17 CCSs receiving cardioactive medication because of cardiomyopathy, tubular dysfunction, and/or hypertension. ‡Hypercholesterolemia defined as fasting LDL cholesterol Ն 3.4 mmol/L and/or use of cholesterol-lowering medication. §Blood samples taken after overnight fast. ʈOverweight defined as BMI Ն 25 kg/m 2 . ¶Renal function measured in 24-hour urine sample; renal dysfunction indicated as Յ 60 mL/minute/1.73 m Table A3 , online only); t-PA and PAI-I as markers of increased fibrinolytic activity were positively associated with any RT. Patients treated with TBI had higher t-PA and PAI-I levels compared with patients not treated with RT (median t-PA, 7.4 [range, 2.5 to 9.6] v 4.5 ng/mL [range, 1.3 to 13.3]; P ϭ .001; median PAI-I, 26 [range, 12 to 176] v 13 ng/mL [range, 3 to 197]; P Ͻ .001, respectively). The ratio of urinary albumin to creatinine as a sign of endothelial damage was associated with platinum exposure (B, 0.3; 95% CI, 0.01 to 0.49).
Vascular Damage and CRFs
The results of logistic regression analyses assessing the association between each of the CRFs and the dependent variables of carotid IMT Ն P 75 (ie, Ն 0.65 mm) and femoral IMT Ն P 75 (ie, Ն 0.56 mm) are summarized in Table 5 . After adjustment for potential confounders, including smoking status, greater carotid IMT was associated with hypertension and overweight (Table 5) . Additional adjustment for cancer treatment variables did not alter these associations (data not 
‫ء‬
Comparison of von Willebrand factor between male CCSs and male controls and between female CCSs and female controls (with v without oral contraceptives) showed no significant differences.
†In 24-hour urine.
shown). Lower FMD was not significantly associated with any of the CRFs (data not shown). Logistic regression analyses showed no association between carotid and fermoral IMTs and endothelial or inflammatory marker proteins (Appendix Table A4 , online only). However, femoral IMT was significantly associated with urinary albumin excretion (Appendix Table A4 ), indicating that greater urinary albumin loss was associated with greater femoral IMT.
DISCUSSION
In our study, greater IMT of both the carotid and femoral arteries was associated with previous RT at a median of 18 years after treatment, especially if RT was administered to the neck or mediastinal region. Compared with sibling controls, CCSs had more endothelial damage, as measured by the endothelial marker proteins PAI-I and t-PA, and an unfavorable cardiovascular risk profile. The prevalence of CRFs was higher in survivors with greater carotid IMT.
Most studies of vascular damage in CCSs have been performed in small cohorts only, addressing the association with previous RT. [7] [8] [9] These studies suggested that survivors treated with neck and/or cranial irradiation had greater carotid IMT compared with controls. 7, 8 Our study covered a much larger cohort of CCSs (n ϭ 277) and clearly indicates that vascular damage is more prevalent in patients whose cancer treatment included RT. Mounting evidence in the general population indicates that greater carotid IMT predicts cardiovascular 
‫ء‬
Corrected for age at diagnosis, sex, and current age. †Reference: no anthracyclines (n ϭ 78). ‡Reference: no RT (n ϭ 103). §In models 3 and 4, RT group 3 not included. ʈNo. of patients excludes those from RT group 3. 
Each CRF was tested in separate model, with adjustment for potential confounders: age at diagnosis, current age, sex, and current smoking. Hypercholesterolemia defined as fasting LDL cholesterol Ն 3.4 mmol/L and/or use of cholesterol-lowering medication. From included potential confounders, higher carotid IMT was associated with male sex (OR, 2.5; 95% CI, 1.1 to 5.0) and current age (OR, 1.2; 95% CI, 1.1 to 1.2). Higher femoral IMT was associated with male sex (OR, 3.3; 95% CI, 1.6 to 5.0) and current age (OR, 1.2; 95% CI, 1.1 to 1.3).
†Reference value Ն 75th percentile.
events. 5, 6, 23 Femoral IMT is also considered to be an independent parameter for predicting coronary artery disease. 24, 25 In our study, we found femoral IMT in CCSs to be associated with any type of RT, especially if administered to the neck or mediastinum. The aortic arch and/or glomus caroticum of patients treated with RT administered to the neck or mediastinum are often included in the irradiation field, resulting in the potential for influence of the baroreceptors, with BP and vascular tonus being altered. Together, these findings suggest that RT-treated CCSs are at risk for long-term vascular damage, including damage to effector organs outside the primary irradiation field, which suggests, in addition, a systemic effect of irradiation.
CCSs who received any type of RT, especially TBI, had higher plasma PAI-I and t-PA levels. Increased levels of PAI-I and t-PA are associated with higher prevalence of coronary artery disease.
26,27
The association of earlier RT and the existence of both vascular damage (ie, increased carotid and femoral IMTs) and endothelial activation (ie, higher plasma PAI-I and t-PA levels) suggest systemic vascular damage.
We found no difference in FMD between CCSs and controls and no association between FMD and any of the treatment groups. Notably, in the assessment of coronary artery disease, FMD has been considered of less value than morphologic parameters, such as IMT. 28 This is in accordance with studies in survivors of adult cancer, which have demonstrated increased endothelial marker protein levels without abnormalities in FMD. 29, 30 Furthermore, because of the crosssectional nature of this study, it is likely that the time-dependent vascular effects of cancer treatment on FMD and inflammatory markers are transient and were not captured at a single time point.
11,29
We found no influence of previous chemotherapy on parameters of vascular damage, despite evidence of association with platinum derivates and anthracyclines. 11, 30 In previous studies of vascular function in survivors of adult cancers, we found an association between platinum-based chemotherapy and microalbuminuria. 13, 30 In the current study, only the ratio of urinary albumin to creatinine was associated with platinum; endothelial damage was not associated with earlier anthracycline exposure in 199 CCSs at a median of 18 years after treatment. Furthermore, anthracyclines did not have an effect on IMT. The much longer follow-up in our study precludes comparison of our results with those of Chow et al. 11 Consequently, endothelial dysfunction as a transient phenomenon after completion of cancer treatment cannot be excluded in our study. Longitudinal studies are needed to address this issue.
In our study, the prevalence of renal dysfunction among CCSs was increased, and there was a tendency toward more hypertension. These factors are known to be associated with increased cardiovascular risk. [31] [32] [33] [34] In particular, CCSs with increased carotid and/or femoral IMTs and those with increased plasma levels of PAI-I and/or t-PA had an unfavorable cardiovascular risk profile, making them more vulnerable to accelerated atherosclerosis and cardiovascular morbidity. Young adults with CRFs are at risk for increased carotid IMT, especially when there is endothelial damage, resulting in subclinical atherosclerosis. [35] [36] [37] [38] Recent findings suggest that childhood and adolescent CRFs and lifestyle are associated with subclinical atherosclerosis and its progression in adulthood. Another recent observation suggests that the adverse effects on metabolic status and vascular function in adolescents and young adults are reversible by treating risk factors like overweight and metabolic syndrome. 39, 40 The impact of the presence of CRFs on lifetime risk of cardiovascular morbidity in the general population makes intervening increasingly relevant. 41 Early intervention with lifestyle improvement seems rational for a high-risk population like CCSs who received RT, especially to the neck or mediastinum.
The strengths of our study are the large sample size, extended follow-up, and large number of sibling controls. Until now, most studies of vascular damage in CCSs determined either vascular function (FMD), vascular structure (carotid IMT), or inflammatory and endothelial marker proteins, whereas we assessed all entities. A limitation of our study is heterogeneity of the cohort, but this was necessary to assess a large-enough sample in this single-institution study.
In conclusion, after potentially cardiovascularly toxic anticancer treatment, adult CCSs clearly had more markers of endothelial damage and an unfavorable cardiovascular risk profile compared with controls. CCSs treated with RT, especially to the neck or mediastinum region, showed both increased carotid IMT and femoral IMT as signs of subclinical atherosclerosis. These direct and indirect effects of irradiation result in abnormalities that are likely to be involved in the pathogenesis of cardiovascular morbidity in CCSs. With an excellent oncologic prognosis, the impact of vascular damage resulting from this cancer treatment on lifetime risk of cardiovascular morbidity is of great clinical importance. Now is the time for CCSs with CRFs and unfavorable lifestyle factors (eg, diet, physical activity) to demand and receive optimal cardiovascular risk management and support for sustainable lifestyle improvement. Professionals caring for long-term CCSs should be made aware of this unmet need. Therefore, we recommend that these young survivors undergo proper follow-up for CRFs and vascular parameters. High-risk survivors can be selected, and rigorous preventive strategies can be evaluated. 
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Corrected for age at diagnosis, sex, current age, and overweight/underweight. †Reference: no anthracyclines (n ϭ 78). ‡Reference: no RT (n ϭ 103). §In models 3 and 4, RT group 3 not included. ʈNo. of patients excludes those from RT group 3. Abbreviations: FMD, flow-mediated vasodilatation; RT, radiotherapy.
